Try
AbbVie Inc.
ABBVUnited States
79 filed reports · 477 financial concepts · 41 earnings calls · 0 media appearances
Filed reports
79 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 135 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 38 | 157 | Mar 2017 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 31 | 5,322 | Jun 2016 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 5,852 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 3, 2026 | 329 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 31, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 8, 2026 | 234 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 29, 2026 | 2 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 20, 2026 | 1,092 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 4, 2026 | 2 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 258 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 31, 2025 | 2 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 4, 2025 | 170 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Jul 31, 2025 | 2 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 9, 2025 | 165 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | Apr 25, 2025 | 2 | Open |
Financial data
477 concepts · 11,331 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial462 concepts · 10,376 facts · Sep 2014 to Jul 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Earnings per share basic58 · Dec 2014 to Jun 2026
- Earnings per share diluted58 · Dec 2014 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Allocated share based compensation expense57 · Dec 2014 to Jun 2026
- Amortization of intangible assets57 · Dec 2014 to Jun 2026
- Comprehensive income net of tax57 · Dec 2014 to Jun 2026
- Costs and expenses57 · Dec 2014 to Jun 2026
- Depreciation57 · Dec 2014 to Jun 2026
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Interest expense (US GAAP)57 · Dec 2014 to Jun 2026
- Interest income expense nonoperating net57 · Dec 2014 to Jun 2026
- Net income loss available to common stockholders basic57 · Dec 2014 to Jun 2026
- Operating income loss57 · Dec 2014 to Jun 2026
- Other nonoperating income expense57 · Dec 2014 to Jun 2026
- Participating securities distributed and undistributed earnings loss diluted57 · Dec 2014 to Jun 2026
- Research and development asset acquired other than through business combination written off57 · Dec 2014 to Jun 2026
- Research and development expense excluding acquired in process cost57 · Dec 2014 to Jun 2026
- Selling general and administrative expense57 · Dec 2014 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities56 · Dec 2014 to Jun 2026
- Increase decrease in accounts receivable56 · Dec 2014 to Jun 2026
- Increase decrease in inventories56 · Dec 2014 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets56 · Dec 2014 to Jun 2026
Product6 concepts · 634 facts · Dec 2014 to Jun 2026
- Revenue315 · Dec 2014 to Jun 2026
- Revenue (excluding assessed tax)306 · Mar 2018 to Mar 2026
- Impairment of intangible assets finitelived7 · Sep 2022 to Dec 2025
- Fair value measurement with unobservable inputs reconciliation recurring basis liability gain loss included in earnings4 · Jun 2019 to Dec 2021
- Impairment of intangible assets excluding goodwill1 · Mar 2023
- Impairment of intangible assets indefinitelived excluding goodwill1 · Dec 2024
Geography1 concepts · 164 facts · Dec 2014 to Dec 2025
- Revenue164 · Dec 2014 to Dec 2025
Guidance8 concepts · 157 facts · Apr 2017 to Jul 2026
- EPS (Diluted) Guidance77 · Apr 2017 to Jul 2026
- EPS (Diluted) Guidance (Adjusted (non-GAAP))46 · Apr 2017 to Feb 2022
- EPS (Diluted) Growth Guidance (Adjusted (non-GAAP))16 · Oct 2017 to May 2020
- Effective Tax Rate Guidance (Adjusted (non-GAAP))6 · Jan 2018 to Jul 2018
- EPS (Diluted) Growth Guidance6 · Jul 2019 to May 2020
- Revenue Growth Guidance2 · Jan 2018
- Revenue Growth Guidance (Constant currency)2 · Feb 2020
- Revenue Guidance2 · Jan 2018
Segments
798 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or serviceus-gaap:ProductOrServiceAxis23 members · 576 facts
- Humira74 · Mar 2018 to Mar 2026
- Duodopa66 · Mar 2018 to Sep 2025
- Imbruvica49 · Mar 2018 to Mar 2026
- Lupron33 · Mar 2018 to Sep 2021
- Duodopa25 · Dec 2014 to Jun 2018
- HUMIRA25 · Dec 2014 to Jun 2018
- Kaletra25 · Dec 2014 to Jun 2018
- Lupron25 · Dec 2014 to Jun 2018
- Sevoflurane25 · Dec 2014 to Jun 2018
- Creon24 · Mar 2018 to Mar 2026
- Imbruvica21 · Dec 2014 to Jun 2018
- Andro Gel19 · Dec 2014 to Jun 2018
- Creon19 · Dec 2014 to Jun 2018
- HCV19 · Dec 2015 to Jun 2018
- Synagis19 · Dec 2014 to Jun 2018
- Synthroid19 · Dec 2014 to Jun 2018
- Kaletra18 · Mar 2018 to Mar 2020
- Other Products17 · Dec 2014 to Jun 2018
- Sevoflurane16 · Mar 2018 to Mar 2020
- Synthroid12 · Mar 2018 to Sep 2021
- Viekira12 · Dec 2014 to Jun 2017
- Andro gel7 · Mar 2018 to Mar 2020
- Synagis7 · Mar 2018 to Mar 2020
Statement geographicalsrt:StatementGeographicalAxis13 members · 120 facts
- BR10 · Dec 2016 to Dec 2025
- CA10 · Dec 2016 to Dec 2025
- DE10 · Dec 2016 to Dec 2025
- ES10 · Dec 2016 to Dec 2025
- FR10 · Dec 2016 to Dec 2025
- GB10 · Dec 2016 to Dec 2025
- IT10 · Dec 2016 to Dec 2025
- JP10 · Dec 2016 to Dec 2025
- Other Countries10 · Dec 2016 to Dec 2025
- US10 · Dec 2016 to Dec 2025
- AU8 · Dec 2018 to Dec 2025
- CN8 · Dec 2018 to Dec 2025
- NL4 · Dec 2016 to Dec 2019
Product or servicesrt:ProductOrServiceAxis8 members · 58 facts
- Other Products45 · Dec 2016 to Jun 2026
- SKYRIZI4 · Jun 2019 to Dec 2021
- Imbruvica2 · Sep 2023 to Sep 2024
- Liletta And Coolsculpting2 · Dec 2023
- Resonic And Durysta2 · Sep 2025 to Dec 2025
- AGN1516071 · Mar 2023
- Emraclidine1 · Dec 2024
- Vuity1 · Sep 2022
Statement geographicalus-gaap:StatementGeographicalAxis11 members · 44 facts
- BR4 · Dec 2014 to Dec 2017
- CA4 · Dec 2014 to Dec 2017
- DE4 · Dec 2014 to Dec 2017
- ES4 · Dec 2014 to Dec 2017
- FR4 · Dec 2014 to Dec 2017
- GB4 · Dec 2014 to Dec 2017
- IT4 · Dec 2014 to Dec 2017
- JP4 · Dec 2014 to Dec 2017
- NL4 · Dec 2014 to Dec 2017
- Other Countries4 · Dec 2014 to Dec 2017
- US4 · Dec 2014 to Dec 2017
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary111 claims from 9 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary218 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes5 claims from 1 reports · Dec 2025
- Risk factors60 risks from 2 annual reports · 2024 to 2025
Earnings calls
41 calls · Jul 2016 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 31, 2026
- FY2026 Q1Apr 29, 2026
- FY2025 Q4Feb 4, 2026
- FY2025 Q3Oct 31, 2025
- FY2025 Q2Jul 31, 2025
- FY2025 Q1Apr 25, 2025
- FY2024 Q4Jan 31, 2025
- FY2024 Q3Oct 30, 2024
- FY2024 Q2Jul 25, 2024
- FY2024 Q1Apr 26, 2024
- FY2023 Q4Feb 2, 2024
- FY2023 Q3Oct 27, 2023
- FY2023 Q2Jul 27, 2023
- FY2023 Q1Apr 27, 2023
- FY2022 Q4Feb 9, 2023
- FY2022 Q3Oct 28, 2022
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.